Amplify Treatments, Testing and Advancements ETF: (GERM)
(Delayed Data from NYSE) As of Mar 18, 2024 03:22 PM ET
$18.07 USD
-0.09 (-0.50%)
Volume: 2,422
ETF Quote Details
Previous Close | 18.16 |
Open | 18.03 |
Bid | 18.01 |
Ask | 18.27 |
Day Low-High | 18.03-18.14 |
52wk Low-High | 15.67-22.00 |
Volume | 2,422 |
NAV (month end) | 18.41 |
Premium (+)/Discount (-) (month end) | -0.25 |
ETF Expense Ratio
Expense Ratio | 0.68% |
Dividend (Yield) | $0.24 (1.33%) |
Issuer | AMPLIFY ETFS |
Benchmark for GERM
PRIME TREATMENTS TESTING & ADVNCMNTS ID
The Prime Treatments, Testing and Advancements Index provides investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.
Fund Summary for GERM
AMPLIFY TREATMENTS TESTNG & ADVNCMNT ETF
The Amplify Treatments, Testing and Advancements ETF seeks investment results that generally correlate, before fees and expenses, to the total return performance of the Prime Treatments, Testing and Advancements Index.